A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib With CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Palbociclib (Primary) ; Tazemetostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 12 Dec 2024 According to Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition, If these two 2-drug combinations prove to be safe, company will amend the protocol to add Part 3 which will evaluate the safety of the 3-drug combination of pre-treatment with PALB followed by co-treatment with TAZ and CPX-351.
- 12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 29 Aug 2023 Status changed from not yet recruiting to recruiting.